DW News published this video item, entitled “Why is Germany’s CureVac vaccine just 48% effective? | Covid-19 Special” – below is their description.
CureVac’s COVID-19 jab did not turn out what many hoped it would be. That’s despite using the same messenger RNA technology as rivals Moderna and BioNTech-Pfizer. CureVac aimed to produce its vaccine primarily for developing countries – as it can be stored more easily than other products. And despite disappointing trial-results the company is sticking to the plan.DW News YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.